IL132477A0 - Methods of screening compounds useful for prevention of infection or pathogenicity - Google Patents

Methods of screening compounds useful for prevention of infection or pathogenicity

Info

Publication number
IL132477A0
IL132477A0 IL13247798A IL13247798A IL132477A0 IL 132477 A0 IL132477 A0 IL 132477A0 IL 13247798 A IL13247798 A IL 13247798A IL 13247798 A IL13247798 A IL 13247798A IL 132477 A0 IL132477 A0 IL 132477A0
Authority
IL
Israel
Prior art keywords
pathogenicity
methods
compounds useful
infection
prevention
Prior art date
Application number
IL13247798A
Other languages
English (en)
Original Assignee
Gen Hospital Corp
Netherlands Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Netherlands Cancer Inst filed Critical Gen Hospital Corp
Publication of IL132477A0 publication Critical patent/IL132477A0/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5097Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving plant cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8281Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for bacterial resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5085Supracellular entities, e.g. tissue, organisms of invertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43526Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
    • G01N2333/4353Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
    • G01N2333/43534Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/874Pseudomonas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
IL13247798A 1997-05-08 1998-05-08 Methods of screening compounds useful for prevention of infection or pathogenicity IL132477A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85292797A 1997-05-08 1997-05-08
US08/962,750 US7166270B1 (en) 1995-03-28 1997-11-03 Methods of screening compounds useful for prevention of infection or pathogenicity
PCT/US1998/009150 WO1998050080A1 (fr) 1997-05-08 1998-05-08 Procedes de criblage de composes utiles pour la prevention de l'infection ou de la pathogenicite

Publications (1)

Publication Number Publication Date
IL132477A0 true IL132477A0 (en) 2001-03-19

Family

ID=27127099

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13247798A IL132477A0 (en) 1997-05-08 1998-05-08 Methods of screening compounds useful for prevention of infection or pathogenicity

Country Status (15)

Country Link
US (1) US7166270B1 (fr)
EP (1) EP1047454B1 (fr)
JP (1) JP2002508749A (fr)
KR (1) KR20010012334A (fr)
CN (1) CN1261810A (fr)
AT (1) ATE333903T1 (fr)
AU (1) AU752575B2 (fr)
CA (1) CA2287774A1 (fr)
DE (1) DE69835376T2 (fr)
IL (1) IL132477A0 (fr)
NO (1) NO995438L (fr)
NZ (1) NZ500508A (fr)
PL (1) PL337576A1 (fr)
TR (1) TR199902742T2 (fr)
WO (1) WO1998050080A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905670B2 (en) 1995-03-28 2005-06-14 The General Hospital Corporation Methods of screening compounds useful for prevention of infection or pathogenicity
WO1999027129A1 (fr) 1997-11-25 1999-06-03 The General Hospital Corporation Sequences nucleotidiques associees a la virulence et leurs utilisations
US6299850B1 (en) 1999-03-16 2001-10-09 The United States Of America As Represented By The Department Of Energy Carbon activation process for increased surface accessibility in electrochemical capacitors
HUP0201142A2 (en) * 1999-04-15 2002-08-28 Devgen Nv Compound screening method
WO2001062978A1 (fr) * 2000-02-25 2001-08-30 The General Hospital Corporation Procedes de depistage de facteurs de virulence enterocoque gram-positive
US7078584B2 (en) 2000-03-17 2006-07-18 The General Hospital Corporation Salmonella typhimurium-infected Caenorhabditis elegans for identifying inhibitors of infection
US7112716B2 (en) 2000-04-06 2006-09-26 The General Hospital Corporation Methods for screening and identifying host pathogen defense genes
US20050119302A1 (en) * 2001-10-30 2005-06-02 Rahme Laurence G. Methods for the prevention or treament of bacterial and fungal infections
KR100848790B1 (ko) * 2006-12-27 2008-07-30 연세대학교 산학협력단 소나무 재선충, 다이플로스캡터 및 예쁜 꼬마선충에 대한살선충제의 고속 스크리닝 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416651D0 (en) 1984-06-29 1984-08-01 Erba Farmitalia Penem derivatives
US5270448A (en) 1990-07-27 1993-12-14 Mycogen Corporation Isolates of Bacillus thuringiensis that are active against nematodes
US5366995A (en) 1991-05-01 1994-11-22 Mycogen Corporation Fatty acid based compositions for the control of established plant infections
JPH08505529A (ja) 1993-01-08 1996-06-18 チバ−ガイギー アクチェンゲゼルシャフト 植物に病気抵抗性をブリーディングする方法
US5641627A (en) 1993-10-25 1997-06-24 Ribogene, Inc. Methods for screening for antimycotics
US6461854B1 (en) * 1995-03-28 2002-10-08 The General Hospital Corporation Methods of screening compounds useful for prevention of infection or pathogenicity

Also Published As

Publication number Publication date
NO995438L (no) 2000-01-03
WO1998050080A1 (fr) 1998-11-12
PL337576A1 (en) 2000-08-28
CA2287774A1 (fr) 1998-11-12
CN1261810A (zh) 2000-08-02
AU7369198A (en) 1998-11-27
NO995438D0 (no) 1999-11-05
EP1047454A4 (fr) 2002-03-27
KR20010012334A (ko) 2001-02-15
US7166270B1 (en) 2007-01-23
NZ500508A (en) 2001-02-23
AU752575B2 (en) 2002-09-26
TR199902742T2 (xx) 2000-04-21
DE69835376T2 (de) 2007-08-23
DE69835376D1 (de) 2006-09-07
JP2002508749A (ja) 2002-03-19
EP1047454A1 (fr) 2000-11-02
ATE333903T1 (de) 2006-08-15
EP1047454B1 (fr) 2006-07-26

Similar Documents

Publication Publication Date Title
PE41395A1 (es) Antagonista de taquiquinina no peptidico
GR3035774T3 (en) Substituted benzolactam compounds as substance p antagonists
HK1046403A1 (en) Nematicidal trifluorobutenes.
ES2106700T3 (es) Procedimiento para la preparacion de derivados de la 4a,5,9,10,11,12-hexahidro-6h-benzofuro(3a,3,2-ef)(2)benzacepinas.
BG105270A (en) Tetrahydropyridoethers
CY2538B1 (en) Tetrahydropyrido compounds
BG102644A (en) Improved concentrated inoculation and infusion solutions for intravasal application
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
IL132477A0 (en) Methods of screening compounds useful for prevention of infection or pathogenicity
EP0932613A4 (fr) Blocage de l'expression de l'aggressine dans s. aureus
EP0828520A4 (fr) Procede de criblage de composes utilises dans la prevention d'infections ou de pathogenese
NZ320259A (en) Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
EP1028754A4 (fr) Prevention d'une immunoreactivite par depletion ou inhibition de cellules presentant l'antigene
HU9700024D0 (en) Imidazopyridin-azolidinones
MX9601957A (es) Proceso para la obtencion de la 2',3'-dideshidro-3'- desoxitimidina polimorfica, forma i.
TR199900016T2 (xx) Benzo $g] kuinolin t�revleri.
NO921491L (no) Indol- og dihydrokinolinaapnere for kaliumkanal
HUP0002781A3 (en) Methods of screening compounds useful for prevention of infection or pathogenicity
IL142088A0 (en) Methods and compositions for inhibiting neoplastic cell growth
BG103321A (en) Method for the preparation of phenoxyphenylsulphonyl halogenides
AU2002323777A1 (en) Methods of screening compounds useful for prevention of infection or pathogenicity
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
MX9602767A (es) Dimaleato de n,n-dietil-8,8-dipropil-2-azaspiro[4,5]decano-2-propanamina.
WO2003056295A3 (fr) Facteurs de virulence des enterocoques